SFMBT2 Inhibitors
SFMBT2 inhibitors encompass a range of chemical compounds that target various epigenetic modifications and processes. These inhibitors often function by altering the chromatin landscape, which can impede the ability of SFMBT2 to effectively bind to chromatin and exert its regulatory functions. For instance, compounds that inhibit DNA methylation enzymes can lead to a reduction in DNA methylation, a modification known to affect chromatin compaction and gene expression. This change in the chromatin structure could subsequently reduce the chromatin binding affinity of SFMBT2, thereby inhibiting its function. Similarly, histone deacetylase inhibitors work by increasing the acetylation levels of histones, which loosens chromatin structure and may disturb the interaction between SFMBT2 and its chromatin targets. This disruption can diminish the regulatory role SFMBT2 plays in gene expression, influencing cellular pathways and functions.
Furthermore, SFMBT2's functionality can be indirectly influenced by compounds that modulate histone methylation patterns. For example, inhibitors of histone methyltransferases can alter histone marks that are recognized by SFMBT2, affecting its ability to bind to these modified histones and regulate gene expression. Other chemical inhibitors may impact protein stability and interactions by preventing the degradation of ubiquitylated proteins, which could affect the molecular environment that SFMBT2 operates within. Additionally, the accumulation of protein and DNA adducts, as a consequence of aldehyde dehydrogenase inhibition, can result in altered protein-DNA interactions, potentially impacting SFMBT2's binding to DNA and its subsequent regulatory activities.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor that reduces DNA methylation. Reduced methylation may lead to the alteration of chromatin structure and subsequently inhibit SFMBT2 function by disrupting its chromatin binding affinity. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
This compound inhibits DNA methylation. By decreasing methylation levels, This compound may affect chromatin compaction and hinder SFMBT2's ability to interact with methylated histones. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $210.00 $242.00 $1434.00 | 2 | |
A histone deacetylase inhibitor which leads to increased acetylation of histones. This modification can alter chromatin structure and thereby potentially reduce the binding efficiency of SFMBT2 to chromatin. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $88.00 $208.00 | 24 | |
A histone deacetylase inhibitor that results in hyperacetylation of histones, possibly disrupting SFMBT2's ability to bind to its chromatin targets due to changes in chromatin architecture. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $196.00 | 9 | |
A potent pan-histone deacetylase inhibitor that can lead to widespread changes in chromatin structure, potentially impairing SFMBT2's chromatin binding and gene regulatory functions. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
This inhibitor also targets histone deacetylases, leading to increased histone acetylation and can interfere with SFMBT2's chromatin interactions and modulatory roles. | ||||||
UNC0638 | 1255580-76-7 | sc-397012 | 10 mg | $315.00 | ||
A selective inhibitor of histone methyltransferases G9a and GLP. By inhibiting these enzymes, this compound may indirectly affect SFMBT2's chromatin binding due to alterations in histone methylation patterns. | ||||||
BIX01294 hydrochloride | 1392399-03-9 | sc-293525 sc-293525A sc-293525B | 1 mg 5 mg 25 mg | $36.00 $110.00 $400.00 | ||
An inhibitor of the histone methyltransferases G9a and GLP, which can modify the histone methylation landscape and potentially disrupt SFMBT2's recognition of methylated histones. | ||||||
EPZ6438 | 1403254-99-8 | sc-507456 | 1 mg | $66.00 | ||
An inhibitor of the histone methyltransferase EZH2. By impacting methylation patterns, it can indirectly influence SFMBT2's chromatin association and function. | ||||||
Chaetocin | 28097-03-2 | sc-200893 | 200 µg | $120.00 | 5 | |
A selective inhibitor of the histone methyltransferase SUV39H1, which can lead to decreased trimethylation of histone H3 at lysine 9, possibly disrupting SFMBT2's binding to these marks. | ||||||